Literature DB >> 16136646

Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial.

Adrian M Di Bisceglie1, Richard K Sterling, Raymond T Chung, James E Everhart, Jules L Dienstag, Herbert L Bonkovsky, Elizabeth C Wright, Gregory T Everson, Karen L Lindsay, Anna S F Lok, William M Lee, Timothy R Morgan, Marc G Ghany, David R Gretch.   

Abstract

BACKGROUND/AIMS: Alpha-fetoprotein (AFP) has been useful in the diagnosis of hepatocellular carcinoma (HCC) but lacks specificity. We assessed serum AFP among patients with chronic hepatitis C and advanced fibrosis to establish predictors of AFP elevations and changes with antiviral therapy.
METHODS: Serum AFP was measured at baseline and on therapy in patients in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C). AFP levels were correlated with patient demographic and clinical features.
RESULTS: Baseline AFP was > or = 20 ng/mL in 191 of 1145 patients (16.6%). Mean AFP values were significantly higher in patients with cirrhosis than in those with bridging fibrosis (22.5 vs. 11.4 ng/mL, P < 0.0001). Factors independently associated with raised serum AFP in patients with cirrhosis were female gender, black race, decreased platelet count, increased serum AST/ALT ratio, serum ferritin, and Mallory bodies in liver biopsies. Serum AFP levels decreased significantly during therapy with pegylated interferon alpha-2a and ribavirin. HCC was identified in six subjects, only three of whom had AFP > 20 ng/mL.
CONCLUSIONS: Among patients with advanced chronic hepatitis C, serum AFP values are frequently elevated, even in the absence of HCC. Factors associated with raised AFP include severity of liver disease, female gender and black race. Serum AFP levels decline during antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16136646     DOI: 10.1016/j.jhep.2005.03.019

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  125 in total

1.  Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.

Authors:  Richard K Sterling; Elizabeth C Wright; Timothy R Morgan; Leonard B Seeff; John C Hoefs; Adrian M Di Bisceglie; Jules L Dienstag; Anna S Lok
Journal:  Am J Gastroenterol       Date:  2011-09-20       Impact factor: 10.864

2.  Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients.

Authors:  Peter Richardson; Zhigang Duan; Jennifer Kramer; Jessica A Davila; Gia L Tyson; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2011-12-07       Impact factor: 11.382

3.  The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma.

Authors:  Mengjun Wang; Karthik Devarajan; Amit G Singal; Jorge A Marrero; Jianliang Dai; Ziding Feng; Jo Ann S Rinaudo; Sudhir Srivastava; Alison Evans; Hie-Won Hann; Yinzhi Lai; Hushan Yang; Timothy M Block; Anand Mehta
Journal:  Cancer Prev Res (Phila)       Date:  2015-12-28

4.  Should AFP (or any biomarkers) be used for HCC surveillance?

Authors:  Hager F Ahmed Mohammed; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2017-04-28

Review 5.  Diagnosis and treatment of hepatocellular carcinoma: An update.

Authors:  Javier Tejeda-Maldonado; Ignacio García-Juárez; Jonathan Aguirre-Valadez; Adrián González-Aguirre; Mario Vilatobá-Chapa; Alejandra Armengol-Alonso; Francisco Escobar-Penagos; Aldo Torre; Juan Francisco Sánchez-Ávila; Diego Luis Carrillo-Pérez
Journal:  World J Hepatol       Date:  2015-03-27

6.  Cord blood -fetoprotein as a predictive index for indirect hyperbilirubinemia in term neonates.

Authors:  Yadollah Zahedpasha; Mousa Ahmadpour-Kacho; Jafar Khalafi; Ali Bijani
Journal:  Caspian J Intern Med       Date:  2011

7.  Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis.

Authors:  Purva Gopal; Adam C Yopp; Akbar K Waljee; Jason Chiang; Mahendra Nehra; Pragathi Kandunoori; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-02       Impact factor: 11.382

Review 8.  Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers.

Authors:  Lisa X Deng; Neil Mehta
Journal:  Dig Dis Sci       Date:  2020-12       Impact factor: 3.199

9.  A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.

Authors:  Hashem B El-Serag; Fasiha Kanwal; Jessica A Davila; Jennifer Kramer; Peter Richardson
Journal:  Gastroenterology       Date:  2014-01-23       Impact factor: 22.682

10.  Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

Authors:  Adrian M Di Bisceglie; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; James E Everhart; Elizabeth C Wright; William M Lee; Anna S Lok; Herbert L Bonkovsky; Timothy R Morgan; Marc G Ghany; Chihiro Morishima; Kristin K Snow; Jules L Dienstag
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.